NextCure, Inc. (NXTC): Price and Financial Metrics


NextCure, Inc. (NXTC)

Today's Latest Price: $9.87 USD

0.32 (-3.14%)

Updated Nov 23 4:00pm

Add NXTC to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

NXTC Stock Summary

  • With a one year PEG ratio of 0.47, NextCure Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than merely 6.08% of US stocks.
  • NXTC's went public 1.54 years ago, making it older than just 2.51% of listed US stocks we're tracking.
  • In terms of volatility of its share price, NXTC is more volatile than 96.13% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to NextCure Inc are DTIL, NTLA, MTEM, KALV, and FULC.
  • Visit NXTC's SEC page to see the company's official filings. To visit the company's web site, go to www.nextcure.com.

NXTC Stock Price Chart Interactive Chart >

Price chart for NXTC

NXTC Price/Volume Stats

Current price $9.87 52-week high $70.98
Prev. close $10.19 52-week low $7.91
Day low $9.84 Volume 189,116
Day high $10.30 Avg. volume 457,632
50-day MA $10.22 Dividend yield N/A
200-day MA $22.43 Market Cap 271.95M

NextCure, Inc. (NXTC) Company Bio


NextCure, Inc. is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases.


NXTC Latest News Stream


Event/Time News Detail
Loading, please wait...

NXTC Latest Social Stream


Loading social stream, please wait...

View Full NXTC Social Stream

Latest NXTC News From Around the Web

Below are the latest news stories about NextCure Inc that investors may wish to consider to help them evaluate NXTC as an investment opportunity.

NXTC CLASS ACTION DEADLINE: Bernstein Liebhard Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against NextCure Inc.

NEW YORK, Sept. 29, 2020 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action that has been filed on behalf of investors that: (i) purchased or acquired the…

PR Newswire | September 29, 2020

NXTC SHAREHOLDER ALERT: Bernstein Liebhard Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against NextCure Inc.

NEW YORK--(BUSINESS WIRE)--Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action that has been filed on behalf of investors that: (i) purchased or acquired the securities of NextCure, Inc. (“NextCure” or the “Company”) (NASDAQ: NXTC) securities between November 5, 2019 to July 14, 2020; and (ii) purchased or acquired NextCure common stock pursuant to or traceable to the Company's Regist

Business Wire | September 28, 2020

ROSEN, A LEADING LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against NextCure, Inc.; Encourages Investors with Losses in Excess of $100K to Contact the Firm - NXTC

NEW YORK, Sept. 28, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between November 5, 2019 and July 14, 2020, inclusive (the "Class…

PR Newswire | September 28, 2020

NXTC INVESTOR ALERT: Bernstein Liebhard is Investigating NextCure Inc. For Violations of the Securities Laws

NEW YORK--(BUSINESS WIRE)--Bernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of NextCure Inc. ("NextCure" or the "Company") (NASDAQ: NXTC) resulting from allegations that NextCure might have issued misleading information to the investing public. If you purchased NextCure securities, and/or would like to discuss your legal rights and options please visit NXTC Shareholder Investigation or contact Matth

Business Wire | September 23, 2020

NXTC Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies NextCure, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm

NEW YORK, Sept. 23, 2020 /PRNewswire/ -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against NextCure, Inc. ("NextCure" or "the Company") (NASDAQ: NXTC) and certain of its officers, on behalf of shareholders who…

PR Newswire | September 23, 2020

Read More 'NXTC' Stories Here

NXTC Price Returns

1-mo -20.60%
3-mo 6.47%
6-mo -71.42%
1-year -73.19%
3-year N/A
5-year N/A
YTD -82.48%
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9863 seconds.